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Conventional immunosuppressive therapies have radically transformed patient survival in systemic lupus
erythematosus (SLE), but their use is associated with considerable toxicity and a substantial proportion of patients
remain refractory to treatment. A more comprehensive understanding of the complexity of SLE
immunopathogenesis has evolved over the past decade and has led to the testing of several biologic agents in
clinical trials. There is a clear need for new therapeutic agents that overcome these issues, and biologic agents offer
exciting prospects as future SLE therapies.
An array of promising new therapies are currently emerging or are under development including B-cell depletion
therapies, agents targeting B-cell survival factors, blockade of T-cell co-stimulation and anti-cytokine therapies, such
as monoclonal antibodies against interleukin-6 and interferon-α.
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Systemic lupus erythematosus (SLE) is a complex auto-
immune rheumatic disease, characterized by unpredict-
able exacerbations and remissions. Clinical manifestations
are variable ranging from arthralgia, photosensitivity and
the classic ‘butterfly’ rash to internal organ involvement,
most notably renal and central nervous system disease [1].
The prevalence of SLE varies significantly in different eth-
nic groups. SLE is more commonly seen in those of Afro-
Caribbean and Asian origin than in Caucasian populations
[2]. The overall prevalence of SLE in the UK is approxi-
mately 28 per 100,000 head of population, rising to ap-
proximately 200 per 100,000 in Afro-Caribbean females [3].
Lupus nephritis remains a major cause of morbidity and
mortality in SLE. There have been major improvements
in the risk of premature mortality in patients with lupus
nephritis [4]. However, despite advances in the clinical
management of lupus nephritis in recent decades with
earlier diagnosis of disease and optimization of the cur-
rently available immunosuppressive regimens, an estimated
10% to 15% of patients progress to end-stage renal disease
(ESRD) [5]. The rate of progression to ESRD and the risk
of premature mortality is likely to be even higher in patients* Correspondence: david.d’cruz@kcl.ac.uk
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reproduction in any medium, provided the orof Afro-Caribbean descent [6]. A significant proportion of
lupus nephritis patients are refractory to conventional im-
munosuppressive agents and the potential side effects of
these therapies remain significant.
A retrospective review of lupus nephritis patients over a
30-year period (1975 to 2005) from a single center showed
that five-year mortality decreased by 60% between the first
and second decades of the study but remained unchanged
over the third decade with rates of 17.2, 7.7 and 4.7%,
respectively, after the diagnosis of renal disease [7]. The
rate of progression to ESRD also reached a plateau in the
third decade. These results suggest that the benefits of con-
ventional immunosuppressive therapies have been maxi-
mized and if further advances in SLE outcomes are to be
achieved, novel therapeutic targets must be developed [7].
Over the last two decades, there have been tremendous
advances in the understanding of the immunopathology of
this autoimmune disorder. A variety of novel therapeutic
targets have been identified and there have been many clin-
ical trials in patients with SLE in an attempt to translate
these new treatments into clinical practice. The results of
these studies have been very mixed and there has been a
steep learning curve for everyone involved in designing
and executing these trials. SLE is a particularly challenging
disease to study due to the broad spectrum of clinical
manifestations and varying patterns of disease activity.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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developed for use in observational clinical studies were
exposed as inadequate when used in therapeutic clinical
trials. This has led to the development of a composite
outcome measure, the Systemic Lupus Erythematosus
Responder Index (SRI), which has become the industry
standard for lupus trials [8]. Another theme that has
emerged is the excessive use of corticosteroids. Not only
are these a major confounder in assessing disease re-
sponse, it is now recognized that high dose corticosteroids
have significant deleterious effects that may contribute to
the development of damage and, hence, long term mor-
bidity and premature mortality [9]. Here we describe novel
therapeutic strategies under development for the treat-
ment of SLE, which are summarized in Table 1.
B-cell depletion therapy
Given that autoantibody production is the hallmark of
SLE, it is not surprising that B cell depletion therapy is a
promising therapeutic option in the management of SLE.
The main drug in current clinical practice is rituximab,
with other drugs in development including epratuzumab.
B cells, including the populations that interact with T cells,Table 1 Summary of potential novel therapeutic options and
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SLE, and it is thought that after B cell depletion, disease
activity may be modified and durable disease remission
achieved, minimizing the use of other immunosuppressive
agents and corticosteroids.Rituximab (anti-CD20)
Rituximab is a chimeric anti-CD20 monoclonal antibody
that has been used off-license in the management of
severe refractory SLE since 2002. The mechanism of ac-
tion of rituximab involves antibody-dependent cell toxicity
(ADCC), complement-dependent cell toxicity (CDC) and
direct apoptosis of CD20+ B lymphocytes which results in
complete B cell depletion [10]. Plasma cells are unaffected
by rituximab as they lack the CD20 surface marker.
A recent review of the efficacy of rituximab in the
management of SLE patients with biopsy-proven severe
lupus nephritis from pooled data in European cohorts
(n = 164) reported the clinical efficacy of rituximab in
clinical practice [11]. This open-label data, showing that
approximately two-thirds of patients previously unre-
sponsive to conventional therapies had clinical benefit,biologics for SLE
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trials (RCTs) of rituximab, which did not meet the pri-
mary and secondary endpoints set out during the trial
design.
The Study to Evaluate the Efficacy and Safety of Rituxi-
mab in Patients With Severe Systemic Lupus Erythematosus
(EXPLORER) included patients with moderate to severe
SLE but excluded lupus nephritis patients (n = 257) [12].
The EXPLORER RCT compared rituximab plus standard
immunosuppressive drugs including mycophenolate mofetil
(MMF) (n = 169) to placebo plus standard immunosup-
pressive therapy, with all patients receiving 10 weeks of
high dose corticosteroids. Published data report the failure
of the EXPLORER trial to show superiority of rituximab or
statistically significant differences in clinical activity when
the two treatment arms were compared [12]. Closer exam-
ination of the data shows that rituximab achieved effective
B cell depletion and, in those patients with positive anti-
dsDNA antibodies and low complement levels, significant
improvements were seen in these parameters in the rituxi-
mab treated patients compared to the placebo group.
The Study to Evaluate the Efficacy and Safety of Rituxi-
mab in Subjects with ISN/RPS Class III or IV Lupus Neph-
ritis (LUNAR) trial compared rituximab plus MMF to
MMF alone for the management of severe proliferative
lupus nephritis class III and class IV. The published results
did not show superiority of the rituximab combination
therapy [13]. As with the EXPLORER study, rituximab ther-
apy achieved B cell depletion as well as improvements in
the levels of anti-dsDNA antibodies and complement levels
compared to the placebo treated patients. Thus, in both
these studies, a biological effect was seen in the rituximab
arms that did not translate into a clinical benefit over and
above standard therapies.
There are many possible explanations for the failure of
the EXPLORER and LUNAR trials such as the relatively
short trial duration and high doses of concomitant corti-
costeroids. Rituximab continues to be used off-label in a
select group of patients with severe refractory SLE. This
off-license use of rituximab takes into account the po-
tential benefits reported from clinical practice and the
possible complications of biologic therapy, such as se-
vere or recurrent infections, adverse drug reactions and
the few case reports of progressive multi-focal leuco-
encephalopathy (PML) [14,15].
An additional benefit of rituximab induction therapy
followed by MMF maintenance therapy for the manage-
ment of severe proliferative lupus nephritis class III and
class IV, is the ability to reduce and eventually withdraw
corticosteroid therapy in patients who respond to treat-
ment [16].
A new treatment strategy termed the Rituxilup regimen
has been pioneered in a center in the United Kingdom.
The Rituxilup regimen avoids the use of concomitantoral corticosteroid therapy after rituximab induction ther-
apy, thereby minimizing the duration of corticosteroid
exposure and steroid side-effects [17]. A proposed ran-
domized controlled trial will be of great clinical rele-
vance in ascertaining the clinical effectiveness, benefits
and consequences of this steroid-sparing regimen.
RING – Rituximab for Lupus Nephritis With Remission
as a Goal, an investigator-initiated randomized inter-
national open multicenter study, aims to determine the
clinical effectiveness of rituximab in achieving complete
renal remission in lupus nephritis patients with per-
sistent proteinuria (≥1 grams/day) despite a minimum
of six months of standard immunosuppressive therapy
(www.clinicaltrials.gov). This study is still at the devel-
opment stage.
Epratuzumab (anti-CD22)
Epratuzumab is an anti-CD22 monoclonal antibody that
is currently under investigation for the management of
moderate to severe SLE and shows great promise.
CD22 is a B cell specific trans-membrane sialo-
glycoprotein which is present on the cell surface of mature
naive B cells and transitional B cells but not present on
memory B cells or plasma cells [18]. CD22 is a lectin-like
adhesion receptor which has an important role to play in
the regulation of B cell function and also forms part of the
B cell activation complex [18]. As an anti-CD22 monoclo-
nal antibody, epratuzumab can cause moderate depletion of
B cells via ADCC; however, unlike rituximab, epratuzumab
does not exhibit CDC or direct apoptosis of B cells [18].
Epratuzumab predominantly targets CD27- B cells such as
naive mature and transitional B cells and it is estimated that
the reduction in peripheral B cell counts in SLE patients
approximates 40% post-epratuzumab therapy [19].
EMBLEM™ is a 12-week, multi-center, randomized,
double-blind, placebo-controlled, phase IIb study to
assess the efficacy and safety of epratuzumab and de-
termine a dose regimen in patients with moderate to
severe SLE. A total of 227 patients were recruited and
randomized to placebo n = 38, epratuzumab 200 mg cumu-
lative dose (100 mg alternate weeks) n = 39, epratuzumab
800 mg cumulative dose (400 mg alternate weeks) n = 38,
epratuzumab 2,400 mg cumulative dose (600 mg weekly)
n = 37, epratuzumab 2,400 mg cumulative dose (1,200 mg
alternate weeks) n = 37, epratuzumab 3,600 mg cumula-
tive dose (1,800 mg alternate weeks) n = 38.
Epratuzumab at a cumulative dose of 2,400 mg was
clinically effective and demonstrated a significant reduc-
tion in disease activity as measured by a composite dis-
ease activity score. Epratuzumab 600 mg weekly was
associated with the greatest improvement in British Isles
Lupus Assessment Group (BILAG)-2004 scores (from A/B
to C/D) than placebo in all organ domains included in the
study. Overall epratuzumab was well tolerated [18].
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of epratuzumab in severe SLE as determined by the pres-
ence of BILAG A (RCT SL0003) and/or moderate patients
with BILAG B in at least two systems (RCT SL0004) were
discontinued due to irregularities in the manufacture of
epratuzumab. The results of patients recruited in these
trials were pooled and indicate the potential benefit of
epratuzumab in facilitating a reduction in prescribed
corticosteroid dose [18].
Two Phase III, randomized, double-blind, placebo-
controlled, multicenter studies of the efficacy and safety
of four 12-week treatment cycles (48 weeks total) of
epratuzumab in SLE subjects with moderate to severe
disease EMBODY™1 & EMBODY™2 have an expected
completion date of February 2014 with a recruitment of
780 patients. The main aim is to evaluate the efficacy,
safety, tolerability and immunogenicity of epratuzumab
in patients with moderate and severe SLE (NCT01262365,
NCT01261793, www.clinicaltrials.gov). A phase III, multi-
center, open-label, extension study to assess the safety
and tolerability of epratuzumab treatment in SLE sub-
jects EMBODY™4 started recruiting in July 2011 and is
aiming to recruit 1,400 patients with a completion date of
February 2016 (NCT01408576, www.clinicaltrials.gov).
Ocrelizumab (anti-CD20)
Ocrelizumab is a humanized anti-CD20 monoclonal anti-
body. In 2010 an independent monitoring board recom-
mended the suspension of clinical trials of ocrelizumab
in rheumatoid arthritis and SLE due to a high frequency
of reported severe and opportunistic infections in the
patients enrolled in the trials. Therefore, the Study to
Evaluate Ocrelizumab in Patients With Nephritis Due
to Systemic Lupus Erythematosus (BELONG) trial was
suspended [20].
The BELONG study had recruited 381 lupus nephritis
class III and class IV patients to study the clinical effi-
cacy and safety of ocrelizumab 400 mg or ocrelizumab
1,000 mg administered at baseline, a fortnight later, then
every four months thereafter. All lupus nephritis patients
enrolled in the study were treated with either intravenous
cyclophosphamide using the EuroLupus regimen or MMF
and high-dose corticosteroids concomitantly. Week 42
data from 221 patients who had enrolled at least 32 weeks
prior to study termination have been reported in abstract
form and, although ocrelizumab is clinically effective in
reducing lupus nephritis disease activity, the data have
not demonstrated superiority to standard immunosup-
pression [20].
Targeting B-cell survival factors
Belimumab (anti-BLys)
Belimumab is a human immunoglobulin G1λ monoclonal
antibody which blocks the binding of the soluble form ofthe cytokine B-lymphocyte stimulator (B-Lys), also known
as B cell activating factor (BAFF), to the transmembrane
activator/calcium modulator/cyclophilin ligand interactor
(TACI) receptor, B-cell maturation (BCMA) receptor and
BAFF receptor 3 (BR3) on B cells and thus interrupts the
B cell survival role of B-Lys [21].
BAFF/BLys is expressed by several cells including den-
dritic cells, monocytes, activated neutrophils and T cells.
It is vital in facilitating the maturation and survival of B
cells via signaling through the BAFF-R, BCMA and TACI
receptors with high, intermediate and low affinity respect-
ively. APRIL, a BAFF homologue proliferation-inducing
ligand binds with higher affinity to the TACI receptor
than BAFF [22]. Dimerization of BAFF and APRIL to
the BCMA receptor is required to support the matur-
ation of plasma cells [22]. A strong interaction of BAFF
to the BAFF-R propagates the maturation and survival
of naive B cells and the interaction of BAFF/BLys, APRIL
and TACI to the TACI-R facilitates immunoglobulin (Ig)
gene class switching in the germinal center [22].
In the presence of an excess amount of BAFF/BLys,
low-affinity self-reactive B cells may survive and mature
into self-reactive auto-antibody secreting plasma cells
implicated in autoimmune disease pathogenesis. As a
result, it has been deduced that the inhibition of BAFF/
BLys by belimumab has therapeutic implications in SLE.
In March 2011 the United States Food and Drug Admin-
istration (FDA) and the European Medicines Evaluation
Agency (EMEA) licensed belimumab as the first new drug
in over 50 years for SLE. Belimumab was licensed as a
biologic agent to be prescribed with standard therapy
for autoantibody-positive adult SLE patients excluding
those with active lupus nephritis and central nervous
system manifestations of SLE.
Belimumab is administered on a weight-based dosing
schedule of belimumab 10 mg/kg as an hour long intraven-
ous infusion fortnightly for three infusions then monthly
thereafter.
A phase III randomized placebo-controlled trial Belimumab
International SLE Study (BLISS-52) conducted between
May 2007 and July 2009 included 865 SLE patients enrolled
in Central and Eastern Europe, Latin America, and Asia
Pacific [19]. A phase III randomized placebo-controlled
trial Belimumab International SLE Study (BLISS-76) was
conducted between February 2007 and February 2010
enrolling 819 patients in North America and Western
and Central Europe [23]. These studies used the com-
posite SRI outcome measure which requires improve-
ment in the SELENA-SLEDAI but no worsening in the
BILAG and Physician Global Assessment scores.
The trial outcome at 52 weeks in BLISS-52 reported
positive clinical response in 44% of those treated with
placebo with standard therapy, 51% of those treated with
belimumab 1 mg/kg with standard therapy and 58% of
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therapy (P = 0.013 and P = 0.0006, respectively) [23].
The trial outcome at 52 weeks in BLISS-76 reported
positive clinical response in 34% of those treated with
placebo with standard therapy, 41% of those treated with
belimumab 1 mg/kg with standard therapy and 43% of
those treated with belimumab 10 mg/kg with standard
therapy (P = 0.10 and P = 0.021, respectively) [23]. How-
ever, at 76 weeks, there was no significant difference in re-
sponder rates between the belimumab and placebo groups.
The BLISS-52 and BLISS-76 clinical trials both ex-
cluded patients with active lupus nephritis. BLISS-LN is
a phase III, randomized, double-blind, placebo-controlled
study to evaluate the efficacy and safety of belimumab plus
standard of care versus placebo plus standard of care in
adult subjects with active lupus nephritis which will provide
clinically relevant information about the use of belimumab
in lupus nephritis NCT01639339 (www.clinicaltrials.gov).
An exploratory analysis of belimumab use in patients
of black ethnicity in the BLISS-52 and BLISS-76 trials
(n = 148) reported lower clinical effectiveness in this
group as compared to other ethnic groups.
A phase III/IV multi-center, randomized, double-blind,
placebo-controlled, 52-week study to evaluate the effi-
cacy and safety of belimumab in adult subjects of black
race with SLE is planned as a future study NCT01632241
(www.clinicaltrials.gov).
Belimumab may be more effective in specific sub-groups
of lupus patients. Published data indicate that belimumab
is significantly more efficacious in SLE patients who
are ds-DNA positive, hypocomplementemic or have
high disease activity as measured by SELENA-SLEDAI
score >10 [24].
In 2012, fatal anaphylaxis was reported in a patient
treated with belimumab and it is now known that there
is a risk of a delayed acute hypersensitivity reaction to
belimumab, especially in patients with multiple drug
allergies. Long-term observational data will provide
further safety and tolerability data on belimumab. At
present the FDA Center for Drug Evaluation and Research
has reviewed the safety labeling for belimumab (www.fda.
gov/Safety/MedWatch/SafetyInformation/ucm299628).
The increased susceptibility to infection after belimumab
treatment may be as a consequence of alterations in the
signaling pathways involving BAFF/BLys and the TACI
receptor. The TACI molecule has a complex role in host
immunity involving activation of B cells and T cell inde-
pendent immune regulation; however, this is yet to be
completely understood [25]. In light of this, it has been
postulated that the post-belimumab low BAFF/BLys
levels result in a reduction in TACI signaling and ham-
per the host immune defenses against pathogens, such
as polysaccharide encapsulated bacteria. Patients treated
with belimumab have an increased susceptibility toinfection, the commonest being pharyngitis, bronchitis,
cystitis and viral gastroenteritis [23]. In the clinical trials
serious infections have been reported in 6% of belimumab-
treated patients as compared to 5.2% in placebo controls
but there have been no reports to date of PML in
belimumab treated patients [26].
Although belimumab received regulatory approval from
the US FDA and the EMEA, its use in some countries has
been restricted until approval by national drug evaluation
organizations. The German Institute for Quality and Effi-
ciency in Health Care (IQWiG) has recommended evalu-
ation of belimumab for additional benefit over optimized
immune-suppression rather than over standard therapy
prior to full approval (www.iqwig.de).
In 2012 The National Institute for Health and Clinical
Excellence (NICE) provided a draft national guidance on
the use of belimumab for SLE in the United Kingdom.
NICE did not recommend belimumab within its licensed
indication as add-on therapy to standard immune-
suppressive drugs in adult patients with active auto-
antibody positive SLE. In making this decision, NICE
considered the clinical trial evidence, clinical specialist
and patient opinions. NICE concluded that the use
of belimumab was not sufficiently cost-effective to
the National Health Service (NHS) in relation to its
reported clinical effectiveness. A final decision will be
expected after the appeals process has been concluded
(www.nice.org.uk).
Blisibimod (anti-B-Lys)
In 2010 a Phase II study called PEARL-SC commenced
with the aim of investigating the efficacy, safety, and toler-
ability of blisibimod, a B lymphocyte stimulatory antagon-
ist, in patients with active SLE. In 2011 an open-label
long-term safety extension trial for patients with SLE who
completed the protocol PEARL-SC was commenced.
In 2012 approval was granted by the EMEA and FDA
for phase III clinical trials of blisibimod, CHABLIS-SC1
and CHABLIS-SC2. These international multicenter, ran-
domized, double-blind trials aim to evaluate the efficacy,
safety, tolerability and immunogenicity of blisibimod in
patients with severe active SLE (SELENA-SLEDAI >10)
despite high-dose corticosteroids NCT01395745 (www.
clinicaltrials.gov).
Tabalumab (anti-B-Lys)
Tabalumab (LY2127399) is a human IgG4 monoclonal
antibody targeting membrane-bound and soluble BAFF. A
phase III, multicenter, randomized, double blind, placebo-
controlled study to evaluate the efficacy and safety of sub-
cutaneous LY2127399 in patients with SLE is expected to
be completed in May 2015 (NCT01196091). Tabalumab is
administered subcutaneously in addition to standard of
care therapy for active SLE (www.clinicaltrials.gov).
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Atacicept is a TACI receptor fusion protein which in-
hibits BLys and APRIL in immature B cells, mature B
cells and plasma cells. It is currently under investigation
as a potential new therapy for SLE and is in a phase
II/III clinical trial for patients with SLE excluding lupus
nephritis [27]. The initial phase II trial of atacicept and
MMF combination therapy for lupus nephritis was
stopped due to a high frequency of reported infections
likely related to a marked reduction in total Ig levels
[28]. The prematurely terminated randomized, double-
blind, placebo-controlled Phase II/III, 52-week study,
APRIL-LN, reported adverse events in the patients ran-
domized to atacicept (n = 4). Patients developed significant
IgG hypogammaglobulinemia below the protocol-defined
criteria for discontinuation (n = 3) and serious infections
including, haemophilus influenza pneumonia, legionella
pneumophilia pneumonia and bacillus bacteremia. Inter-
estingly, atacicept trials in rheumatoid arthritis have not
yielded this severity of adverse events [29]. This implies
that the immunopathogenesis of lupus nephritis may have
influenced the results of this atacicept trial.
Blockade of T-cell co-stimulation
Abatacept (CTLA-4-Ig fusion protein)
Blockade of the co-stimulatory interactions between T
and B lymphocytes can induce immunological tolerance.
The most well characterized T lymphocyte co-stimulatory
ligand is CD28, a glycoprotein which interacts with the
co-stimulatory receptors B7-1 (CD80) and B7-2 (CD86).
CTLA4 (cytotoxic T-lymphocyte antigen) is expressed on
activated T cells and interacts with B7 with higher affinity
than CD28 resulting in a negative feedback mechanism
that inhibits T cell activation [30-32]. Abatacept is a fusion
protein consisting of CTLA-4 combined with the Fc por-
tion of human IgG1 (CTLA-4-Ig). Combination therapy
of CTLA-4-Ig and cyclophosphamide significantly reduces
proteinuria, autoantibody titres and improves mortality
in murine lupus nephritis [33-35]. However, a randomized
controlled trial of abatacept in 175 SLE patients failed to
meet its primary end-point of a reduction of the propor-
tion of patients with a new SLE flare [36]. Approximately
one-fifth of the patients included in this study were sero-
negative for ANAs and anti-dsDNA. There were, however
some improvements in quality of life measures by the SF-
36 physical component scores, fatigue and sleep problem
scores in the abatacept treated group. Patients in this study
primarily had musculoskeletal and dermatologic features
of SLE and the trial was not specifically designed to exam-
ine the role of abatacept in lupus nephritis.
A 12-month Phase II/III double-blind placebo controlled
trial in proliferative lupus nephritis failed to meet its
primary end-point of time to complete renal response
as defined as glomerular filtration rate within 10% ofpre-flare/screening value, urinary protein creatinine ra-
tio <0.26 mg/mg and inactive urinary sediment [37].
However when the same data were analyzed using differ-
ent outcome measures, with complete response defined as
serum creatinine either normal or ≤125% of baseline,
urinary protein creatinine ratio <0.5 g/g, and prednisone
dose ≤10 mg/d at study day 365, the study showed a
positive outcome in favor of abatacept [38]. This high-
lights the importance of choosing outcomes measures
in clinical trials of lupus nephritis and the necessity for
standardization of outcomes across studies.
Anti-CD40 ligand
CD40 ligand (CD40L) is a transmembrane glycoprotein
belonging to the tumor necrosis factor (TNF) super
family which binds with CD40 on the surface of B-cells
and macrophages. The interaction between CD40/CD40L
plays a pivotal role in B-cell class switching [39]. CD40L is
over expressed in murine lupus models and monoclonal
antibodies against CD40L have successfully treated murine
lupus nephritis [40]. There have been two clinical trials
of humanized anti-CD40L monoclonal antibodies (IDEC-
131 and BG9588) in SLE patients. Eighty-five SLE patients
treated with IDEC-131 failed to demonstrate clinical
improvement as compared to placebo at 20 weeks [41].
A trial of 28 lupus nephritis patients treated with BG9588
showed initial promise with reduced anti-dsDNA titres and
increasing complement levels but was discontinued prema-
turely due to unexpected thrombo-embolic side effects
[42]. Given the lack of efficacy and toxicity demonstrated
in these studies, it is unlikely that anti-CD40L will progress
to larger clinical trials in SLE patients.
Cytokine therapies
Tocilizumab (anti-IL-6)
IL-6 is a pleiotropic cytokine with both pro-inflammatory
and anti-inflammatory properties and has been implicated
in the pathogenesis of lupus nephritis. Exogenous IL-6
increases autoantibody production and accelerates pro-
gression of nephritis in both the NZB/NZW and BXSB
lupus mouse models [43,44]. Treatment of lupus prone
mice with an IL-6 monoclonal antibody decreases anti-
dsDNA titres and proteinuria and reduces mortality [45,46].
In SLE patients, IL-6 levels have been shown to correlate
with clinical activity and anti-dsDNA antibody levels
[47,48]. Urinary excretion of IL-6 is increased in prolifera-
tive lupus nephritis and is reduced following cyclophospha-
mide therapy [49,50].
Tocilizumab is a fully humanized monoclonal antibody
against the IL-6 receptor and prevents binding of IL-6 to
both membrane bound and soluble IL-6 receptor. A
phase I trial over a 12 week period has demonstrated the
safety and tolerability of tocilizumab in SLE patients.
While active urinary sediment and anti-dsDNA antibody
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The short duration of the study renders it difficult to draw
conclusions as to the longer term effects of tocilizumab
in the treatment of lupus nephritis. Randomized con-
trolled trials of tocilizumab in SLE are awaited. Sirukumab
(CNTO 136) a human monoclonal antibody that targets
IL-6 is currently in a phase II study in lupus nephritis
(NCT01273389) (www.clinicaltrials.gov).
Targeting interferon-α
Recent studies of SLE patients and data from murine
models of lupus, suggest that inappropriate activation of
type I IFNs play an essential role in SLE pathogenesis.
Microarray gene expression analysis has shown wide-
spread activation of IFN-inducible genes in SLE patients
which correlates with disease activity [52,53]. In addition,
IFN pathway activation has been associated with lupus
nephritis activity [54]. A scoring system based on expres-
sion of type I IFN-inducible mRNAs, which may divide
SLE patients into two distinct subgroups has been pro-
posed to enable type I IFN-inducible genes to be used as
biomarkers to identify patients who might respond better
to anti-type I IFN treatment [36]. Given the role of IFN-α
in the host defense against viral infection, close clinical
monitoring is mandatory in the development of any po-
tential agents targeting this pathway.
Sifalimumab, a fully human anti-IFN-α monoclonal anti-
body, induced a dose-dependent inhibition of type I IFN-
induced mRNAs (type I IFN signature) in whole blood in
a phase I study. No increase in viral infections was noted
and a general trend towards improvement in disease activ-
ity was seen [55]. Further studies examining the efficacy of
sifalimumab in SLE are in recruitment (NCT01283139)
(www.clinicaltrials.gov). A Phase II clinical trial evaluating
rontalizumab, a recombinant humanized monoclonal anti-
body to IFN-α for SLE is also ongoing (NCT00962832)
(www.clinicaltrials.gov).
The efficacy and safety of rontalizumab, a recombinant
humanized monoclonal antibody to IFN-α was recently
assessed in a randomized, double-blind, placebo-controlled
phase II trial in adults with moderate to severe non-renal
SLE. An abstract by Kalunian K et al. entitled ‘Efficacy and
Safety of Rontalizumab (Anti-Interferon Alpha) in SLE
Subjects with Restricted Immunosuppressant Use: Results
of a Randomized, Double Blind, Placebo-Controlled Phase
2 Study’ was presented at the American College of Rheuma-
tology Annual Scientific Conference in November 2012.
In the initial part of the study, SLE patients received
either 750 mg intravenously of rontalizumab or placebo
for four weeks. In the second part of the study, SLE patients
received either 300 mg subcutaneously of rontalizumab
or placebo for two weeks. Overall, response rates at 24
weeks as measured by BILAG and SRI were similar be-
tween rontalizumab and placebo. However, in patientstaking >10 mg/kg of steroids daily, rontalizumab was more
effective in reducing lupus disease activity than placebo.
Patients were further analyzed as per their IFN gene
expression signature, which showed that rontalizumab




The complement system plays an important role in the
pathophysiology of SLE although individual complement
components have distinct and varied functions in the
disease process. Early components of the complement
cascade are critical in the clearance of immune complexes
and apoptotic material. Their absence in congenital C3 or
C4 deficiency predisposes individuals to development of
SLE. Activation of terminal complement components is
associated with exacerbations of disease, particularly in
lupus nephritis.
Monoclonal antibodies that specifically inhibit terminal
complement activation while preserving early complement
function have been developed. Eculizumab, a monoclonal
antibody directed against the complement protein C5,
inhibits the cleavage of C5 to C5a and C5b and thus
blocks the formation of the terminal membrane attack
complex C5b-9 [56]. Anti-C5 therapy delays onset of
proteinuria, improves renal histology and survival in mur-
ine lupus nephritis [57]. A phase I trial of eculizumab in
SLE demonstrated safety and tolerability, but no clear clin-
ical improvements were seen by day 28 and 56 of the
study [58]. To date there have been no further clinical tri-
als to examine the potential efficacy of this therapy in SLE.
Targeting Fcγ receptor IIB
Fcγ receptors are a heterogeneous group of hematopoietic
cell surface glycoproteins that recognize the Fc portion
of specific Ig isotypes, facilitating antibody-antigen in-
teractions with effector cells and, thus, play a key role in
the clearance of immune complexes [56]. Fcγ receptor
IIB (FcγRIIB) is the sole inhibitory receptor in the Fcγ
receptor family and competes with activatory Fcγ recep-
tors expressed on immune cells for pathogenic immune
complexes. FcγRIIB may also interfere with formation
of memory/plasma cells that develop autoantibodies
[56]. Treatment of lupus-prone NZB/NZW F1 mice with
recombinant soluble FcγRIIB significantly delayed onset of
proteinuria, reduced histopathological findings and im-
proved survival [57]. Currently a soluble FcγRIIB (SM101)
is undergoing phase II trials in SLE and primary immune
thrombocytopenia (ITP).
Laquinimod
Laquinimod is an oral quinoline-3-carboxamide small
molecule which to date has been mainly investigated in
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In MS, laquinimod biases the CD4+ phenotype in favor
of Th2/Th3 cytokine production and inhibits disease
development and infiltration of inflammatory cells into
the CNS [58,59]. Laquinimod also suppresses major histo-
compatibility class II antigen presentation and down-
regulates epitope spreading [60]. Laquinimod is currently
in phase II trials in lupus arthritis and lupus nephritis.
(www.clinicaltrials.gov).
Janus kinase (JAK) and spleen tyrosine kinase (Syk)
inhibitors
Tofacitinib (JAK inhibitor)
Tofacitinib is a Janus kinase (JAK) selective inhibitor
which has been approved as the first oral biologic for
the management of rheumatoid arthritis. JAKs are essen-
tial for signal transduction of cytokines and contribute
to inflammatory responses [59]. Targeting JAKs in SLE
would be a logical therapeutic option which can be stud-
ied further starting with trials to determine the safety,
pharmacodynamics and efficacy of these drugs in SLE.
Fostamatinib (Syk inhibitor)
Spleen tyrosine kinase (Syk) is implicated in the B cell
immunopathogenesis of SLE and is a potential thera-
peutic target. Syk inhibitors have been shown to prevent
the onset of skin and renal disease in lupus-prone mice.
In addition, Syk inhibitors reduce inflammatory arthritis.
Fostamatinib is an oral Syk inhibitor being evaluated for
the management of autoimmune rheumatic diseases [60].
Discussion
The management of SLE is likely to change significantly
with the introduction of new biological therapies and
the discovery of other therapeutic targets. The exact role
of these drugs will be determined after completion of
the trials and with clinical experience. It is envisioned
that the majority of the biological therapies will initially
be reserved for patients who have failed to respond satis-
factorily to optimal conventional immunosuppressive
drugs. The new biological drugs will need to be used ap-
propriately to target disease remission; reduction of the
disease severity; frequency of lupus flares and the subse-
quent high morbidity associated with lupus.
Conventional immunosuppressive therapies have rad-
ically transformed patient survival in SLE, but their use
is associated with considerable toxicity and a substantial
proportion of patients remain refractory to treatment. A
more comprehensive understanding of the complexity
of SLE immunopathogenesis has evolved over the past
decade and has led to the testing of several biologic
agents in clinical trials. An array of promising new therap-
ies are yet to emerge or are under development. There is
a clear need for new therapeutic strategies that overcomethese issues, and biologic agents offer exciting prospects as
future SLE therapies. The role of new therapeutic agents to
date has chiefly centered on SLE patients who have been
refractory to conventional therapies. There are few clinical
trials examining their role as first line induction or main-
tenance therapy. Questions remain as to how these ther-
apies can potentially be combined with existing proven
treatments and indeed with one another to achieve max-
imum clinical benefit while minimizing toxicity. Although
so far many biologics have been generally well tolerated,
we must not be complacent regarding potential toxicity
of these new agents, as we do not yet know the long-
term effects of these medications on the immune system.
Rituximab is currently used off-license for the manage-
ment of severe refractory SLE and is likely to continue to
be used for this indication due to overall positive clinical
experience.
Based on the clinical trial and extension study data,
belimumab has a modest level of clinical effectiveness
when used in combination with standard immunosup-
pressive drugs in autoantibody-positive SLE patients. The
BILAG data at week 52 of the BLISS trials suggested more
favorable outcomes in the mucocutaneous, musculoskel-
etal domains. The SELENA-SLEDAI cutaneous, muscu-
loskeletal, immunologic, vascular and CNS components
significantly improved at week 52 in the BLISS trials.
Physicians will, therefore, be inclined to closely monitor
patients on belimumab and switch to alternate thera-
peutic regimens if the clinical response is inadequate
after six months. SLE patients of black ethnicity are to
be studied in greater numbers than in the original BLISS
trials in order to ascertain whether or not belimumab is
beneficial in this group of patients. As belimumab use
becomes more prevalent and the results of the on-going
belimumab clinical trials are published, the group of
SLE patients likely to benefit the most from this drug
may be identified and this will guide future use of this
medication.
The place for other therapeutic agents in development for
the management of SLE, such as epratuzumab, blisibimod,
tabalumab and atacicept, as induction or maintenance ther-
apies will be determined after robust reviews of the clinical
trial data which are expected upon completion of the stud-
ies. It is anticipated that only drugs which show long-term
clinical effectiveness, benefit as steroid-sparing agents and
satisfactory safety profiles in SLE will gain approval for
clinical use.
Some novel biologic therapies have been associated
with significant toxicity leading to premature discon-
tinuation of clinical trials such as the association of
anti-CD40L and thrombo-embolic events and the high fre-
quency of reported severe and opportunistic infections as-
sociated with ocrelizumab. Although some drugs have not
progressed to phase II or III clinical trials after phase I
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FcγRIIB and small molecule targets is on-going and may
yield important results for the future of SLE management.
Health economic studies will be essential in determin-
ing the future use of the new therapeutic agents in SLE
and may influence the international use of these drugs.
A number of key questions remain. How can these
therapies be potentially combined with existing proven
treatments and indeed with one another to achieve max-
imum clinical benefit with minimal side-effects, such as
increased risk of serious infection. As is clear to all phy-
sicians involved in the day to day management of SLE
patients, this is a heterogeneous disease and there is not
one therapeutic regimen suitable for all. With a deeper
understanding of the pathophysiology of SLE particularly
from a genetic perspective, the era of personalized ther-
apy may represent the greatest advance that is yet to
come in optimizing treatment of SLE.
Conclusions
Conventional immunosuppressive therapies have radic-
ally transformed patient survival in SLE, but their use is
associated with considerable toxicity and a substantial
proportion of patients remain refractory to treatment. A
more comprehensive understanding of the complexity of
SLE immunopathogenesis has evolved over the past dec-
ade and has led to the testing of several biologic agents
directed against new molecular targets in clinical trials.
An array of promising new therapies is yet to emerge or
is under development. There is a clear need for new
therapeutic agents that overcome these issues, and bio-
logic agents offer exciting prospects as future SLE ther-
apies. Several challenges still remain in designing clinical
trials in SLE. One of the main issues is that conventional
therapies have been optimized and are effective in the
majority of patients. There is, therefore, quite a high bar
for new therapies to demonstrate a significant benefit
over conventional approaches and progress is likely to
be incremental rather than revolutionary.
The role of new therapeutic agents has chiefly centered
on SLE patients who have been refractory to conventional
therapies. There are few clinical trials examining their role
as first line induction or maintenance therapy. Questions
remain around how these therapies can potentially be
combined with existing proven treatments and indeed
with one another to achieve maximum clinical benefit
while minimizing toxicity. As is clear to all physicians
involved in the day to day management of SLE patients,
this is a heterogeneous disease and there is no single
therapeutic regimen suitable for all. With a deeper un-
derstanding of the pathophysiology of SLE particularly
from a genetic perspective, the era of personalized therapy
may represent the greatest advance that is yet to come in
optimizing treatment of SLE.Abbreviations
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